A detailed history of American Portfolios Advisors transactions in Cassava Sciences Inc stock. As of the latest transaction made, American Portfolios Advisors holds 2,300 shares of SAVA stock, worth $67,689. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,300
Holding current value
$67,689
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$16.33 - $51.06 $37,558 - $117,438
2,300 New
2,300 $96.2 Million
Q3 2021

Mar 22, 2023

BUY
$41.79 - $135.3 $246,561 - $798,270
5,900 Added 256.52%
8,200 $509 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.18B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.